retatrutide pen peptide 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in RETATRUTIDE Reusable Pen : Research

Yet medicine rarely gives benefit without trade-offs

This increases glucosedependent insulin secretion, decreases glucagon, slows gastric emptying, and activates satiety centers in the hypothalamus, leading to reduced hunger, smaller portions, and improved postmeal glucose control

Learn more on ClinicalTrials.gov: CT-996 is a once daily oral small molecule agonist of the GLP-1 receptor being developed for the treatment of obesity and type 2 diabetes

What About "Clinical Trials" and "Expanded Access"

Mechanisms of L-cell GLP-1 secretion Physiologically, L-cells, which are most common in the distal parts of the intestines [15], are stimulated to secrete all their secretory products (GLP-1, GLP-2, gut-derived glucagon [also called glicentin], peptide tyrosine tyrosine, oxyntomodulin) in response to nutrient ingestion [16, 17]

Multiple extracellular signals promote osteoblast survival and apoptosis